Previous 10 | Next 10 |
2023-08-29 00:15:03 ET Summary Compass Therapeutics is developing antibody therapies for cancers, with their lead candidate being CTX-009, a dual inhibitor of VEGF-A and DLL4. The company has upcoming topline data from their colorectal cancer and biliary tract cancer programs, as ...
2023-08-03 10:04:44 ET Compass Therapeutics press release ( NASDAQ: CMPX ): Q2 GAAP EPS of -$0.09. As of June 30, 2023, cash and marketable securities were $169 million as compared to $187 million as of December 31, 2022 For further details see: Compass Therapeut...
Continuing to enroll patients in a U.S. Phase 2 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced colorectal cancer (CRC); initial data from this study is expected in the second half of 2023 Opened 20 clinical sites and continues to enroll patients in a U.S. Phase ...
2023-06-22 16:26:11 ET Compass Therapeutics ( NASDAQ: CMPX ) said Thursday that it will be added to the Russell 2000 and Russell 3000 Indexes. The addition is part of the Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2...
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that it will be added to the Russell 2000 ...
BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following...
2023-05-04 13:22:22 ET Compass Therapeutics press release ( NASDAQ: CMPX ): Q1 GAAP EPS of -$0.06. As of March 31, 2023, cash and marketable securities were $175 million as compared to $187 million as of December 31, 2022, providing the Company with an anticipated cash run...
Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half of 2024 Continue to enroll in a U.S. Phase 2 study of CTX-009 in patients with advanced color...
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the H.C. Wai...
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel 2...
News, Short Squeeze, Breakout and More Instantly...
Compass Therapeutics Inc. Company Name:
CMPX Stock Symbol:
OTCMKTS Market:
Compass Therapeutics Inc. Website:
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside cha...
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Sc...
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors....